Women in Biohealth (WiB) is an organization that was started in the fall of 2017 to provide a platform to empower and connect women in the biohealth community.
Learn more
Find resources to define, build, grow, and unite our community
We are stronger together!
Annual Report
We host and participate in a number of events. Explore and
learn about all of the upcoming that could be valuable to you.
we offer benefits that help you attract and retain high tech
talent and establish your position in the industry.
Initiative
a platform for women in biohealth
to connect and uplift one another
and provide opportunities for professional
development, career mentoring,
and networking.
Women in Biohealth today
Initiative
the growing healthcare technology
ecosystem in southeastern Wisconsin
and providing resources to entrepreneurs.
HealthTechMKE today
Initiative
Campaign is focused on bringing
top talent to Wisconsin and our
member companies.
webpage today
Wisconsin: Building the Future of Healthcare
We build things in Wisconsin. We are good at it. Wisconsin is building the next frontier through its biohealth industry where biosciences, digital health, medical devices, diagnostics and biomanufacturing are converging to form an integrated health solutions platform. See what is happening in Wisconsin.
HealthTechMKE is focused on connecting the growing healthcare technology ecosystem in southeastern Wisconsin and providing resources to entrepreneurs.
Learn moreMedallion Members
Latest News
People with both cancer and COVID-19 are more likely to be Black, have chronic conditions, live in poorer zip codes
Read the full press release here Among people with cancer, people diagnosed with COVID-19 were more likely to be Black, have active cancer, have chronic conditions and live in zip ..
UW-Health on the future of public health: Role of COVID-19 vaccine boosters
Read the full press release here Ongoing studies of immunity provided by available COVID-19 vaccines in the United States show that protection lasts at least six months, but many a ..
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Read the full press release here Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded ..